Mission Possible: Advances in MYC Therapeutic Targeting in Cancer
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
MYC is a master transcriptional regulator that controls almost all cellular processes. Over the last several decades, researchers have strived to define the context-dependent transcriptional gene programs that are controlled by MYC, as well as the mechanisms that regulate MYC function, in an effort to better understand the contribution of this oncoprotein to cancer progression. There are a wealth of data indicating that deregulation of MYC activity occurs in a large number of cancers and significantly contributes to disease progression, metastatic potential, and therapeutic resistance. Although the therapeutic targeting of MYC in cancer is highly desirable, there remain substantial structural and functional challenges that have impeded direct MYC-targeted drug development and efficacy. While efforts to drug the 'undruggable' may seem futile given these challenges and considering the broad reach of MYC, significant strides have been made to identify points of regulation that can be exploited for therapeutic purposes. These include targeting the deregulation of MYC transcription in cancer through small-molecule inhibitors that induce epigenetic silencing or that regulate the G-quadruplex structures within the MYC promoter. Alternatively, compounds that disrupt the DNA-binding activities of MYC have been the long-standing focus of many research groups, since this method would prevent downstream MYC oncogenic activities regardless of upstream alterations. Finally, proteins involved in the post-translational regulation of MYC have been identified as important surrogate targets to reduce MYC activity downstream of aberrant cell stimulatory signals. Given the complex regulation of the MYC signaling pathway, a combination of these approaches may provide the most durable response, but this has yet to be shown. Here, we provide a comprehensive overview of the different therapeutic strategies being employed to target oncogenic MYC function, with a focus on post-translational mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Chen, W., Arroyo, J. D., Timmons, J. C., Possemato, R., & Hahn, W. C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1103 · Cited by 159
RetractedVogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Dang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390
Comprehensive Characterization of Cancer Driver Genes and Mutations
Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A., Colaprico, A., Wendl, M. C., Kim, J., Reardon, B., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.060 · Cited by 2,256
Reflecting on 25 years with MYC
Meyer, N., & Penn, L. Z. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2231 · Cited by 1,575
The Myc/Max/Mad Network and the Transcriptional Control of Cell Behavior
Grandori, C., Cowley, S. M., James, L. P., & Eisenman, R. N. (2000) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.16.1.653 · Cited by 1,333
Eilers, M., & Eisenman, R. N. (2008) · Genes & Development · doi:10.1101/gad.1712408 · Cited by 927
Intrinsic Disorder in Transcription Factors
Liu, J., Perumal, N. B., Oldfield, C. J., Su, E. W., Uversky, V. N., & Dunker, A. K. (2006) · Biochemistry · doi:10.1021/bi0602718 · Cited by 792
Yeh, E., Cunningham, M., Arnold, H., Chasse, D., Monteith, T., Ivaldi, G., Hahn, W. C., Stukenberg, P. T., Shenolikar, S., Uchida, T., et al. (2004) · Nature Cell Biology · doi:10.1038/ncb1110 · Cited by 791
Self-citationCIP2A inhibits PP2A in human malignancies
Junttila, M. R., Puustinen, P., Niemelä, M., Ahola, R., Arnold, H., Böttzauw, T., Ala-aho, R., Nielsen, C., Ivaska, J., Taya, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.044 · Cited by 677
Self-citationMorris, E. J., Jha, S., Restaino, C. R., Dayananth, P., Zhu, H., Cooper, A., Carr, D., Deng, Y., Jin, W., Black, S., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0070 · Cited by 676
BET inhibitor resistance emerges from leukaemia stem cells
Fong, C. Y., Gilan, O., Lam, E. Y. N., Rubin, A. F., Ftouni, S., Tyler, D., Stanley, K., Sinha, D., Yeh, P., Morison, J., et al. (2015) · Nature · doi:10.1038/nature14888 · Cited by 545
MYC: Connecting selective transcriptional control to global RNA production
Kress, T. R., Sabò, A., & Amati, B. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3984 · Cited by 521
Protein phosphatase 2A regulatory subunits and cancer
Eichhorn, P. J. A., Creyghton, M. P., & Bernards, R. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.05.005 · Cited by 513
Farrell, A. S., & Sears, R. C. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014365 · Cited by 468
Self-citationPan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas
Schaub, F. X., Dhankani, V., Berger, A. C., Trivedi, M., Richardson, A. B., Shaw, R., Zhao, W., Zhang, X., Ventura, A., Liu, Y., et al. (2018) · Cell Systems · doi:10.1016/j.cels.2018.03.003 · Cited by 431
An Overview of MYC and Its Interactome
Conacci-Sorrell, M., McFerrin, L., & Eisenman, R. N. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014357 · Cited by 408
Multiple pathways regulated by the tumor suppressor PP2A in transformation
Westermarck, J., & Hahn, W. C. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.02.001 · Cited by 344
All roads lead to PP 2A: exploiting the therapeutic potential of this phosphatase
Sangodkar, J., Farrington, C. C., McClinch, K., Galsky, M. D., Kastrinsky, D. B., & Narla, G. (2016) · The FEBS Journal · doi:10.1111/febs.13573 · Cited by 312
Wei, S., Kozono, S., Kats, L., Nechama, M., Li, W., Guarnerio, J., Luo, M., You, M.-H., Yao, Y., Kondo, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3839 · Cited by 272
Arnold, H. K., & Sears, R. C. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.7.2832-2844.2006 · Cited by 251
Self-citationPhenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia
Gutierrez, A., Pan, L., Groen, R. W. J., Baleydier, F., Kentsis, A., Marineau, J., Grebliunaite, R., Kozakewich, E., Reed, C., Pflumio, F., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci65093 · Cited by 220
Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth
Sangodkar, J., Perl, A., Tohme, R., Kiselar, J., Kastrinsky, D. B., Zaware, N., Izadmehr, S., Mazhar, S., Wiredja, D. D., O’Connor, C. M., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89548 · Cited by 196
Self-citationIdentification of PP2A Complexes and Pathways Involved in Cell Transformation
Sablina, A. A., Hector, M., Colpaert, N., & Hahn, W. C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2855 · Cited by 193
Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer
Janghorban, M., Farrell, A. S., Allen-Petersen, B. L., Pelz, C., Daniel, C. J., Oddo, J., Langer, E. M., Christensen, D. J., & Sears, R. C. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317630111 · Cited by 186
Self-citationDifferentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer
Risom, T., Langer, E. M., Chapman, M. P., Rantala, J., Fields, A. J., Boniface, C., Alvarez, M. J., Kendsersky, N. D., Pelz, C. R., Johnson-Camacho, K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05729-w · Cited by 174
Self-citationCarabet, L. A., Rennie, P. S., & Cherkasov, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010120 · Cited by 172
Chemical and structural studies provide a mechanistic basis for recognition of the MYC G-quadruplex
Calabrese, D. R., Chen, X., Leon, E. C., Gaikwad, S. M., Phyo, Z., Hewitt, W. M., Alden, S., Hilimire, T. A., He, F., Michalowski, A. M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06315-w · Cited by 172
Khanna, A., Pimanda, J. E., & Westermarck, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1994 · Cited by 154
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells
Kauko, O., O’Connor, C. M., Kulesskiy, E., Sangodkar, J., Aakula, A., Izadmehr, S., Yetukuri, L., Yadav, B., Padzik, A., Laajala, T. D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aaq1093 · Cited by 149
Ruvolo, P. P. (2016) · BBA Clinical · doi:10.1016/j.bbacli.2016.08.002 · Cited by 143
BioID identifies novel c-MYC interacting partners in cultured cells and xenograft tumors
Dingar, D., Kalkat, M., Chan, P.-K., Srikumar, T., Bailey, S. D., Tu, W. B., Coyaud, E., Ponzielli, R., Kolyar, M., Jurisica, I., et al. (2015) · Journal of Proteomics · doi:10.1016/j.jprot.2014.09.029 · Cited by 131
Stabilization of the Max Homodimer with a Small Molecule Attenuates Myc-Driven Transcription
Struntz, N. B., Chen, A., Deutzmann, A., Wilson, R. M., Stefan, E., Evans, H. L., Ramirez, M. A., Liang, T., Caballero, F., Wildschut, M. H. E., et al. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.02.009 · Cited by 130
CIP2A is a target of bortezomib in human triple negative breast cancer cells
Tseng, L.-M., Liu, C.-Y., Chang, K.-C., Chu, P.-Y., Shiau, C.-W., & Chen, K.-F. (2012) · Breast Cancer Research · doi:10.1186/bcr3175 · Cited by 122
Targeting Inhibitors of the Tumor Suppressor PP2A for the Treatment of Pancreatic Cancer
Farrell, A. S., Allen-Petersen, B., Daniel, C. J., Wang, X., Wang, Z., Rodriguez, S., Impey, S., Oddo, J., Vitek, M. P., Lopez, C., et al. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0542 · Cited by 114
Self-citationArnold, H. K., & Sears, R. C. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9128-9 · Cited by 111
Self-citationHu, M.-H., Wang, Y.-Q., Yu, Z.-Y., Hu, L.-N., Ou, T.-M., Chen, S.-B., Huang, Z.-S., & Tan, J.-H. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01697 · Cited by 101
Jung, L. A., Gebhardt, A., Koelmel, W., Ade, C. P., Walz, S., Kuper, J., von Eyss, B., Letschert, S., Redel, C., d'Artista, L., et al. (2017) · Oncogene · doi:10.1038/onc.2016.354 · Cited by 101
Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56
Wang, J., Okkeri, J., Pavic, K., Wang, Z., Kauko, O., Halonen, T., Sarek, G., Ojala, P. M., Rao, Z., Xu, W., et al. (2017) · The EMBO Reports · doi:10.15252/embr.201642788 · Cited by 95
Allen-Petersen, B. L., Risom, T., Feng, Z., Wang, Z., Jenny, Z. P., Thoma, M. C., Pelz, K. R., Morton, J. P., Sansom, O. J., Lopez, C. D., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-0717 · Cited by 85
Self-citationSmall-molecule perturbation of competing interactions between c-Myc and Max
Follis, A. V., Hammoudeh, D. I., Daab, A. T., & Metallo, S. J. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.12.025 · Cited by 60
Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids
Wang, H., Teriete, P., Hu, A., Raveendra-Panickar, D., Pendelton, K., Lazo, J. S., Eiseman, J., Holien, T., Misund, K., Oliynyk, G., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6116 · Cited by 53
Cited by
The MYC oncogene — the grand orchestrator of cancer growth and immune evasion
Dhanasekaran, R., Deutzmann, A., Mahauad-Fernandez, W. D., Hansen, A. S., Gouw, A. M., & Felsher, D. W. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00549-2 · Cited by 986
Therapeutic targeting of “undruggable” MYC
Llombart, V., & Mansour, M. R. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2021.103756 · Cited by 472
MYC protein interactors in gene transcription and cancer
Lourenco, C., Resetca, D., Redel, C., Lin, P., MacDonald, A. S., Ciaccio, R., Kenney, T. M. G., Wei, Y., Andrews, D. W., Sunnerhagen, M., et al. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00367-9 · Cited by 347
Targeting WD Repeat-Containing Protein 5 (WDR5): A Medicinal Chemistry Perspective
Chen, X., Xu, J., Wang, X., Long, G., You, Q., & Guo, X. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00037 · Cited by 63
A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer
Lier, S., Sellmer, A., Orben, F., Heinzlmeir, S., Krauß, L., Schneeweis, C., Hassan, Z., Schneider, C., Patricia Gloria Schäfer, A., Pongratz, H., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105505 · Cited by 37
Metadata
- Authors
- Allen-Petersen, B. L., & Sears, R. C.
- Venue
- BioDrugs
- Published
- 2019-08-07
- Volume
- 33
- Issue
- 5
- Pages
- 539-553
- ISSN
- 1172-7039 (ISSN-L)
- 1173-8804
- 1179-190X
- OpenAlex
- W2966445105
- Cited by
- 148
- References
- 44
- FWCI
- 8.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.